Clinical Trials of Multivalent Opioid Vaccine Components
NCT04458545
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Currently, abuse of prescription opioid analgesics and heroin is a serious problem in the U.S. Although several medications, including methadone, buprenorphine, and naltrexone, are available and effective in treating opioid use disorder (OUD), long-term relapse rates remain high. The current study is designed to examine a new approach to treating OUD, namely use of a vaccine targeted against oxycodone [Oxy(Gly)4-sKLH], one of the most commonly abused prescription opioids.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Opioid-use Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 59 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- New York State Psychiatric Institute
- Last updated on ClinicalTrials.gov
- April 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 1
- Clinilabs Drug Development Corporation · Eatontown, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.